Alto Neuroscience

Psychedelics Precision Psychiatry Company Nabs $60M In Series B Round For Advanced Clinical Trials

Alto Neuroscience Inc. received an additional $25 million in equity investment by Alpha Wave Ventures, bringing total Series B raised funding to approximately $60 million and total equity capital raised to approximately $100 million since its foundation in 2019, plus a recently closed credit facility agreement with investment fir

Novamind Posts Record High Revenue Of CA$2.45M, Up 32% QoQ

Psychedelics-focused mental health company Novamind Inc. (CSE:NM) (OTCQB: NVMDF) (FSE: HN2) reported its financial results for the three and six months ended December 31, 2021.